Agilon Health, Inc.
AGL · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.64 | -0.13 | 0.83 | -0.05 |
| FCF Yield | -9.10% | -3.64% | -2.48% | -1.50% |
| EV / EBITDA | -2.92 | -30.28 | -84.71 | -25.56 |
| Quality | ||||
| ROIC | -50.28% | -30.16% | -9.55% | -31.99% |
| Gross Margin | 0.08% | 1.61% | 4.15% | 4.17% |
| Cash Conversion Ratio | 0.22 | 0.59 | 1.22 | 0.36 |
| Growth | ||||
| Revenue 3-Year CAGR | 36.40% | 41.56% | 25.15% | 24.19% |
| Free Cash Flow Growth | 62.02% | -14.40% | -1.17% | -190.86% |
| Safety | ||||
| Net Debt / EBITDA | 0.66 | 0.33 | 6.26 | 2.58 |
| Interest Coverage | -47.29 | -34.87 | -24.58 | -64.10 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 244.67 | 0.00 |
| Cash Conversion Cycle | -8.18 | -3.51 | 43.39 | 35.63 |